The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart.

1. Pulmonary Arterial Hypertension (PAH)
Market - Global Industry Analysis, Size,
Share, Growth, Trends and Forecast
upto 2020
The global pulmonary arterial hypertension (PAH) market is
progressing at a high CAGR of 17.90% within a forecast period
of 2014 to 2020. This market was recorded at US$4.04 bn in
2013, and is expected to reach US$5.19 bn by the end of 2020.
The data is presented in a unique and comprehensive manner in
a research report released by Transparency Market Research,
titled “Pulmonary Arterial Hypertension (PAH) Market - Global
Industry Analysis, Size, Share, Growth, Trends and Forecast
2014 – 2020.”
Pulmonary arterial hypertension is when the blood pressure
inside the small arteries within the lungs increases. PAH can
cause swelling of legs, fainting, dizziness, and shortness of
breath, among other more serious symptoms. One of the biggest
problems that a patient with PAH suffers is an extremely low
tolerance to exercise. PAH can escalate into pulmonary vascular
resistance and cause the failure of the right ventricle.
According to the report, the primary driver for the global PAH
market is the list of newly-approved drugs and medical products

2. aimed at treating PAH. A large number of medical products are
already approved, while more are still in the pipeline. Another
factor promoting the growth of the global PAH market is the
increasing number of leaps taken in research and development
efforts, aided by government policies and other initiatives.
Browse Full Research Report on Pulmonary Arterial
Hypertension (PAH) Market:
http://www.transparencymarketresearch.com/pulmonary-
arterial-hypertension-therapeutics.html
The report provides a segmented analysis of the global PAH
market. These segments are sorted within the categories of drug
class and geography. The report also provides an extensive
analysis of the pipeline drugs in the global PAH market.
In terms of drug class, the global PAH market is segmented into
soluble guanylate cyclase (sGC) stimulators, phosphodiesterase-
5 (PDE-5) inhibitors, endothelin receptor antagonists (ERAs),
and prostacyclin and prostacyclin analogs. Of these, the report’s
authors have put the prostacyclin and prostacyclin analogs
segment ahead of the ERA segment, which means that the
segment will lead the global PAH market by 2023, surpassing
the current leader, ERAs.

3. The report’s geographical segmentation of the global PAH
market reveals Asia Pacific to be the fastest-growing region for
the given forecast period.
The growth rate of this region is attributed to major
opportunities that will be found in Australia, New Zealand,
Japan, China, and India. Enterprises operating in these regions
could take advantage of these opportunities and increase their
profits and presence in the market.
The report, however, states one of the major restraints on the
global PAH market as the challenges faced by the Rest of the
World PAH market. The report’s study shows that most of the
nations in the Rest of the World region possess a low level of
awareness of this market’s products. Therefore, this region is
showing a much slower growth rate when compared to the
regions of North America or Europe.
The key players in the global pulmonary arterial hypertension
market are United Therapeutics Corp., Novartis International
AG, Pfizer Inc., GlaxoSmithKline plc, Bayer HealthCare, Gilead
Sciences Inc., and Actelion Pharmaceuticals Ltd.

4. Browse Full Press Release on Pulmonary Arterial
Hypertension (PAH) Market:
About Us
Transparency Market Research (TMR) is a global market
intelligence company providing business information reports
and services. The company’s exclusive blend of quantitative
forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of
analysts, researchers, and consultants use proprietary data
sources and various tools and techniques to gather and analyze
information.
TMR’s data repository is continuously updated and revised by a
team of research experts so that it always reflects the latest
trends and information. With extensive research and analysis
capabilities, Transparency Market Research employs rigorous
primary and secondary research techniques to develop
distinctive data sets and research material for business reports.
Press Release

5. Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com